Keltic Pharma Therapeutics

0 followers

In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

Headquarters

Ireland

Employees

1-10

Links


Org chart

Andrew Tobin
Chief Executive Officer and Founder
Collapse
No reports!

Teams

This company has no teams yet


Offices

This company has no offices yet